a Department of Biotechnology, Dayananda Sagar College of Engineering , Bangalore , India.
Crit Rev Microbiol. 2019 May;45(3):315-333. doi: 10.1080/1040841X.2019.1600472. Epub 2019 Apr 23.
(AB) is one of the most notorious and opportunistic pathogens, which caused high morbidity and mortality rate and World Health Organization (WHO) declared this bacterium as priority-1 pathogen in 2017. The current antibacterial agents, such as colistins, carbapenems, and tigecyclines have limited applications, which necessitate novel and alternative therapeutic remedies. Thus, the understanding of recent perspectives on the virulent factors and antibiotic resistance mechanism exhibited by the bacteria are extremely important. In addition to many combinatorial therapies of antibacterial, there is several natural compounds demonstrated significant antibacterial potential towards these bacteria. The computational systems biology and high throughput screening approaches provide crucial insights in identifying novel drug targets and lead molecules with therapeutics potential. Hence, this review provides profound insight on the recent aspects of the virulent factors associated with AB, role of biofilm formation in drug resistance and the mechanisms of multidrug resistance. This review further illustrates the status of current therapeutic agents, scope, and applications of natural therapeutics, such as herbal medicines and role of computational biology, immunoinformatics and virtual screening in novel lead developments. Thus, this review provides novel insight on latest developments in drug-resistance mechanism of multidrug-resistant (MDRAB) and discovery of probable therapeutic interventions.
(AB) 是一种臭名昭著且具有机会主义的病原体,它导致了高发病率和死亡率,世界卫生组织 (WHO) 在 2017 年宣布该细菌为优先级 1 的病原体。目前的抗菌药物,如黏菌素、碳青霉烯类和替加环素,应用有限,因此需要新的和替代的治疗方法。因此,了解细菌表现出的毒力因子和抗生素耐药机制的最新观点非常重要。除了许多抗菌的联合治疗方法外,还有几种天然化合物对这些细菌表现出显著的抗菌潜力。计算系统生物学和高通量筛选方法为确定具有治疗潜力的新型药物靶点和先导分子提供了重要的见解。因此,本综述深入探讨了与 AB 相关的毒力因子、生物膜形成在耐药性中的作用以及多药耐药性的机制等方面的最新研究进展。本综述进一步说明了当前治疗剂的现状、天然疗法(如草药)的范围和应用,以及计算生物学、免疫信息学和虚拟筛选在新型先导化合物开发中的作用。因此,本综述为多药耐药性 (MDRAB) 的耐药机制和可能的治疗干预措施的最新发展提供了新的见解。